We're on a mission to transform life sciences analytics

We're driven by the idea that today's drug discovery and disease research teams deserve modern tools to produce better insights and ultimately better outcomes for the world. That's why we've brought three decades of experience in AI, analytics, and data management to life sciences. We're backed by leaders in biotech and healthcare determined to find a better way to manage drug discovery and disease detection.

Our Leadership

Bryan Ivory

Co-founder, President & CTO

Bryan is an expert software architect and engineer with 20 years of experience in digital product development. Prior to co-founding Limmi, Bryan led product development teams building world-class machine learning and data management , all while revolutionizing how the insurance industry uses and applies artificial intelligence. Previously he served as Engineering Director at Viasat, leading and building  large scale data and AI products for commercial & government applications.

Trevor Vieweg

Co-founder, Chairman of the Board

Trevor has spent the past 15 years as an executive leading product teams in multiple technology sectors. Prior to co-founding Limmi, Trevor served as CTO of Sea Machines, a leading provider of AI-powered autonomous marine vessels. Prior to this he served as Head of Product Development at Viasat, overseeing data & AI teams for products reaching tens of millions of customers a month.

Rob Lozuk

Board Member

In the past decade alone, Rob served as Thermo Fisher’s Director of Business Development and Americas Marketing, as well as Senior Vice President of Commercial Operations at Sequenom, and President of Specific Diagnostics. Most recently, Rob was Chief Business Officer of Cardea Bio, that recently sold to Paragraf. Rob currently serves as CEO of Syantra, a groundbreaking cancer and disease detection platform.

Todd Lewis

Board Member

Todd has served as CTO of multiple industry leading companies, most recently as VP & CTO of Viasat's fixed broadband business, overseeing investments and technology operations across  a $1B business. Todd's deep expertise in AI and data science is invaluable to the team.  

Karim Kader, MD, PhD

Chairman, Advisory Board

Karim Kader, MD, Ph.D., is a board-certified urologist who specializes in detecting, treating, and preventing prostate cancer. Dr. Kader is nationally recognized for his expertise in performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer. He has been the Principal Investigator on multiple clinical projects and has been published extensively.